Plain-English translation of NCT06899165 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —a naturally occurring compound from certain mushrooms—combined with professional therapy can help reduce depression, anxiety, and stress in adults whose parents survived genocide. The study recognizes that trauma experienced by parents can affect their children's mental health across generations, and there are currently no specialized treatments for this specific type of inherited trauma. This research aims to see if this medication, given in a safe, controlled setting with trained therapists, might offer relief.
Children of genocide survivors often experience depression, anxiety, and emotional stress linked to what their parents endured—even though they didn't directly experience the genocide themselves. Right now, there are no proven treatments designed specifically for this type of inherited trauma, so researchers want to test whether this medication combined with therapy could help.
You likely qualify if…
You likely don't qualify if…
If you're accepted into the study, you'll first go through a screening period (up to 4 weeks) with phone calls and consent discussions. Then you'll work with study doctors to safely adjust or pause any psychiatric medications you're on. Over approximately 14 weeks, you'll attend weekly therapy sessions with trained therapists and receive two doses of the medication about 3–4 weeks apart, with structured support before, during, and after each dose. You'll also complete regular questionnaires and assessments to track how you're doing throughout the study.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States